Beta Bionics (BBNX)
Beta Bionics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus.
6.0M
Short interest
settlement 2026-09-30
3.3
Days to cover
-6.7 days vs prior
63.4%
Short share of volume
2026-10-23
7,946
Fails to deliver
settlement 2026-09-18
Tue 27 Oct
Next earnings
estimated date
-$2.4M
Insider flow, 90 days
0 buys, 13 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 41 settlements in the table, 41 in the chart. JSONAs of 30 September 2026, short interest in BBNX is 6,046,389 shares, down 3,354,302 shares over the last month. Over the last 41 readings it ranged from 209,284 shares (31 January 2025) to 10,617,768 shares (15 September 2026). At the reported average volume of 1.9M shares a day that is 3.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bbnx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 6,046,389 | -43.0% | 1,859,712 | 3.25 |
| 2026-09-15 | 10,617,768 | +12.9% | 1,070,962 | 9.91 |
| 2026-08-31 | 9,400,691 | +25.4% | 1,043,173 | 9.01 |
| 2026-08-14 | 7,494,706 | -1.4% | 1,369,658 | 5.47 |
| 2026-07-31 | 7,604,900 | +15.1% | 1,263,408 | 6.02 |
| 2026-07-15 | 6,609,679 | -3.1% | 948,708 | 6.97 |
| 2026-06-30 | 6,819,825 | +45.9% | 1,155,462 | 5.90 |
| 2026-06-15 | 4,674,427 | -10.1% | 1,042,160 | 4.49 |
| 2026-05-29 | 5,199,951 | -8.6% | 721,094 | 7.21 |
| 2026-05-15 | 5,688,126 | -8.2% | 624,527 | 9.11 |
| 2026-04-30 | 6,194,778 | -13.2% | 1,196,395 | 5.18 |
| 2026-04-15 | 7,137,067 | -6.1% | 1,078,547 | 6.62 |
| 2026-03-31 | 7,598,093 | +8.5% | 1,160,297 | 6.55 |
| 2026-03-13 | 7,005,310 | +24.5% | 1,104,702 | 6.34 |
| 2026-02-27 | 5,626,149 | -2.2% | 1,319,369 | 4.26 |
| 2026-02-13 | 5,753,937 | +5.0% | 1,058,178 | 5.44 |
| 2026-01-30 | 5,479,017 | -1.3% | 1,032,928 | 5.30 |
| 2026-01-15 | 5,551,550 | -24.0% | 1,989,334 | 2.79 |
| 2025-12-31 | 7,301,052 | +81.6% | 1,075,359 | 6.79 |
| 2025-12-15 | 4,020,336 | +4.1% | 938,064 | 4.29 |
| 2025-11-28 | 3,860,691 | +8.1% | 426,966 | 9.04 |
| 2025-11-14 | 3,572,312 | -0.9% | 576,204 | 6.20 |
| 2025-10-31 | 3,603,465 | -13.6% | 889,214 | 4.05 |
| 2025-10-15 | 4,169,413 | -34.7% | 474,959 | 8.78 |
| 2025-09-30 | 6,383,216 | +64.4% | 1,361,260 | 4.69 |
| 2025-09-15 | 3,882,499 | +24.8% | 806,486 | 4.81 |
| 2025-08-29 | 3,110,854 | +16.6% | 597,702 | 5.20 |
| 2025-08-15 | 2,668,323 | -36.3% | 598,941 | 4.46 |
| 2025-07-31 | 4,187,831 | -12.8% | 686,955 | 6.10 |
| 2025-07-15 | 4,802,756 | -2.0% | 418,474 | 11.48 |
| 2025-06-30 | 4,903,188 | +3.6% | 506,127 | 9.69 |
| 2025-06-13 | 4,731,224 | +14.4% | 585,861 | 8.08 |
| 2025-05-30 | 4,133,957 | +16.3% | 521,750 | 7.92 |
| 2025-05-15 | 3,555,929 | +0.4% | 496,586 | 7.16 |
| 2025-04-30 | 3,540,321 | +4.5% | 349,066 | 10.14 |
| 2025-04-15 | 3,388,237 | +8.0% | 499,935 | 6.78 |
| 2025-03-31 | 3,137,712 | +159.8% | 858,204 | 3.66 |
| 2025-03-14 | 1,207,551 | +2.2% | 434,252 | 2.78 |
| 2025-02-28 | 1,181,734 | +25.0% | 249,496 | 4.74 |
| 2025-02-14 | 945,109 | +351.6% | 332,878 | 2.84 |
| 2025-01-31 | 209,284 | +100.0% | 693,945 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of BBNX volume is 63.4%, down 15.6 points over the last five sessions. Over the last 30 readings it ranged from 25.9% (16 September 2026) to 85.4% (19 October 2026). The latest reading is 3.7 points above the 30-session average of 59.7%, on 374K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 237K | 374K | 63.4% | 0 |
| 2026-10-22 | 181K | 246K | 73.8% | 0 |
| 2026-10-21 | 322K | 516K | 62.5% | 0 |
| 2026-10-20 | 78K | 167K | 46.7% | 0 |
| 2026-10-19 | 268K | 314K | 85.4% | 0 |
| 2026-10-16 | 133K | 169K | 79.0% | 0 |
| 2026-10-15 | 179K | 250K | 71.6% | 0 |
| 2026-10-14 | 225K | 352K | 63.8% | 18 |
| 2026-10-13 | 123K | 165K | 74.6% | 0 |
| 2026-10-12 | 189K | 303K | 62.3% | 6 |
| 2026-10-09 | 133K | 222K | 60.0% | 1 |
| 2026-10-08 | 189K | 278K | 68.0% | 0 |
| 2026-10-07 | 105K | 200K | 52.3% | 2 |
| 2026-10-06 | 169K | 220K | 76.9% | 7 |
| 2026-10-05 | 99K | 199K | 49.7% | 0 |
| 2026-10-02 | 107K | 195K | 55.2% | 2,600 |
| 2026-10-01 | 237K | 314K | 75.6% | 100 |
| 2026-09-30 | 194K | 401K | 48.4% | 100 |
| 2026-09-29 | 194K | 292K | 66.3% | 0 |
| 2026-09-28 | 260K | 543K | 47.9% | 0 |
| 2026-09-25 | 278K | 427K | 65.0% | 0 |
| 2026-09-24 | 165K | 225K | 73.3% | 0 |
| 2026-09-23 | 254K | 495K | 51.4% | 732 |
| 2026-09-22 | 162K | 406K | 39.9% | 0 |
| 2026-09-21 | 174K | 296K | 58.7% | 0 |
| 2026-09-18 | 198K | 382K | 51.8% | 0 |
| 2026-09-17 | 432K | 1.1M | 38.0% | 462 |
| 2026-09-16 | 741K | 2.9M | 25.9% | 1,500 |
| 2026-09-15 | 342K | 609K | 56.2% | 0 |
| 2026-09-14 | 279K | 592K | 47.2% | 7,936 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in BBNX is 7,946 shares, up 1,757 shares over the last settlement date. Over the last 30 readings it ranged from 100 shares (24 June 2026) to 171,998 shares (4 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 7,946 | $21.43 | $170K |
| 2026-09-17 | 6,189 | $22.18 | $137K |
| 2026-09-03 | 1,924 | $19.42 | $37K |
| 2026-08-27 | 2,171 | $19.34 | $42K |
| 2026-08-26 | 774 | $19.34 | $15K |
| 2026-08-25 | 7,313 | $19.73 | $144K |
| 2026-08-24 | 100 | $19.05 | $2K |
| 2026-08-18 | 15,779 | $17.56 | $277K |
| 2026-08-10 | 37,696 | $15.90 | $599K |
| 2026-08-06 | 107 | $13.91 | $1K |
| 2026-08-05 | 248 | $14.57 | $4K |
| 2026-08-04 | 171,998 | $13.35 | $2.3M |
| 2026-07-30 | 215 | $15.17 | $3K |
| 2026-07-21 | 551 | $17.82 | $10K |
| 2026-07-20 | 27,846 | $17.29 | $481K |
| 2026-07-07 | 2,808 | $16.72 | $47K |
| 2026-06-30 | 2,427 | $17.00 | $41K |
| 2026-06-29 | 97,089 | $16.82 | $1.6M |
| 2026-06-24 | 100 | $13.67 | $1K |
| 2026-06-15 | 967 | $14.53 | $14K |
| 2026-06-12 | 1,253 | $14.69 | $18K |
| 2026-06-10 | 1,143 | $14.39 | $16K |
| 2026-06-08 | 3,668 | $13.89 | $51K |
| 2026-06-04 | 7,508 | $12.45 | $93K |
| 2026-06-03 | 8,989 | $12.79 | $115K |
| 2026-06-02 | 49,699 | $12.80 | $636K |
| 2026-06-01 | 49,668 | $12.12 | $602K |
| 2026-05-29 | 50,510 | $12.10 | $611K |
| 2026-05-28 | 6,435 | $11.63 | $75K |
| 2026-05-27 | 5,770 | $11.72 | $68K |
Insider trades
SEC Form 4, newest first. JSONInsiders at BBNX reported 13 open-market sells worth $2.4M in the last 90 days and no open-market buys. Latest filing: Hopman Mark (Chief Commercial Officer) on 2026-10-14.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Hopman Mark | Chief Commercial Officer | Sell | 775 | $17.35 | $13K | 55K |
| 2026-10-01 | Hopman Mark | Chief Commercial Officer | Sell | 370 | $18.96 | $7K | 56K |
| 2026-09-22 | Jones Christy | Director | Sell | 6K | $23.00 | $148K | 20K |
| 2026-09-16 | Mensinger Mike | Chief Product Officer | Sell | 3K | $22.00 | $58K | 177K |
| 2026-09-16 | Hopman Mark | Chief Commercial Officer | Sell | 31K | $20.13 | $620K | 56K |
| 2026-09-14 | Hopman Mark | Chief Commercial Officer | Sell | 775 | $15.52 | $12K | 86K |
| 2026-09-09 | Hopman Mark | Chief Commercial Officer | Sell | 37K | $18.46 | $681K | 87K |
| 2026-09-03 | Saint Sean | President & CEO | Sell | 6K | $20.08 | $113K | 398K |
| 2026-09-02 | Russell Steven Jon | Chief Medical Officer | Sell | 4K | $19.11 | $81K | 170K |
| 2026-09-02 | Saint Sean | President & CEO | Sell | 17K | $19.11 | $322K | 404K |
| 2026-09-02 | Feider Stephen | Chief Financial Officer | Sell | 7K | $19.11 | $128K | 159K |
| 2026-09-02 | Mensinger Mike | Chief Product Officer | Sell | 4K | $19.11 | $84K | 180K |
| 2026-09-02 | Hopman Mark | Chief Commercial Officer | Sell | 5K | $19.11 | $102K | 124K |
| 2026-06-29 | Feider Stephen | Chief Financial Officer | Sell | 5K | $17.03 | $83K | 166K |
| 2026-06-29 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 5K | $5.10 | $25K | 171K |
| 2026-06-26 | Feider Stephen | Chief Financial Officer | Sell | 5K | $17.05 | $87K | 166K |
| 2026-06-26 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 5K | $5.10 | $25K | 171K |
| 2026-06-24 | Hopman Mark | Chief Commercial Officer | Sell | 1K | $15.01 | $19K | 129K |
| 2026-06-24 | Jones Christy | Director | Sell | 1K | $15.00 | $21K | 26K |
| 2026-06-04 | Hopman Mark | Chief Commercial Officer | Sell | 275 | $12.31 | $3K | 131K |
| 2026-06-04 | Jones Christy | Director | Sell | 3K | $14.00 | $39K | 27K |
| 2026-06-02 | Russell Steven Jon | Chief Medical Officer | Sell | 4K | $12.61 | $53K | 174K |
| 2026-06-02 | Saint Sean | President & CEO | Sell | 17K | $12.61 | $213K | 421K |
| 2026-06-02 | Feider Stephen | Chief Financial Officer | Sell | 7K | $12.61 | $84K | 166K |
| 2026-06-02 | Mensinger Mike | Chief Product Officer | Sell | 4K | $12.61 | $55K | 184K |
| 2026-06-02 | Hopman Mark | Chief Commercial Officer | Sell | 5K | $12.61 | $67K | 131K |
| 2026-05-22 | Lezack Adam | Director | Sell | 998 | $11.21 | $11K | 27K |
| 2026-05-21 | Jones Christy | Director | Grant | 17K | $0.00 | $0 | 30K |
| 2026-05-21 | Jones Christy | Director | Sell | 2K | $9.95 | $20K | 13K |
| 2026-05-21 | Lezack Adam | Director | Grant | 17K | $0.00 | $0 | 28K |
| 2026-05-21 | Lezack Adam | Director | Sell | 1K | $9.95 | $10K | 11K |
| 2026-05-21 | Palasis Maria | Director | Grant | 17K | $0.00 | $0 | 29K |
| 2026-05-21 | Dearen Danny L. | Director | Grant | 17K | $0.00 | $0 | 32K |
| 2026-05-21 | CARNEY SEAN | Director | Grant | 17K | $0.00 | $0 | 32K |
| 2026-05-21 | MICHEL GERARD J | Director | Grant | 17K | $0.00 | $0 | 34K |
| 2026-03-04 | Hopman Mark | Chief Commercial Officer | Sell | 353 | $11.57 | $4K | 139K |
| 2026-03-02 | Russell Steven Jon | Chief Medical Officer | Sell | 1K | $12.36 | $13K | 179K |
| 2026-03-02 | Saint Sean | President & CEO | Sell | 3K | $12.36 | $42K | 438K |
| 2026-03-02 | Feider Stephen | Chief Financial Officer | Sell | 1K | $12.36 | $18K | 173K |
| 2026-03-02 | Mensinger Mike | Chief Product Officer | Sell | 1K | $12.36 | $13K | 189K |
| 2026-03-02 | Hopman Mark | Chief Commercial Officer | Sell | 834 | $12.36 | $10K | 139K |
| 2026-02-27 | Russell Steven Jon | Chief Medical Officer | Grant | 109K | $0.00 | $0 | 180K |
| 2026-02-27 | Saint Sean | President & CEO | Grant | 343K | $0.00 | $0 | 441K |
| 2026-02-27 | Feider Stephen | Chief Financial Officer | Grant | 132K | $0.00 | $0 | 174K |
| 2026-02-27 | Mensinger Mike | Chief Product Officer | Grant | 109K | $0.00 | $0 | 190K |
| 2026-02-27 | Hopman Mark | Chief Commercial Officer | Grant | 109K | $0.00 | $0 | 140K |
| 2026-01-13 | Jones Christy | Director | Grant | 4K | $0.00 | $0 | 15K |
| 2026-01-13 | Lezack Adam | Director | Grant | 4K | $0.00 | $0 | 12K |
| 2026-01-13 | Palasis Maria | Director | Grant | 4K | $0.00 | $0 | 12K |
| 2026-01-13 | Dearen Danny L. | Director | Grant | 4K | $0.00 | $0 | 15K |
| 2026-01-13 | CARNEY SEAN | Director | Grant | 4K | $0.00 | $0 | 15K |
| 2026-01-13 | MICHEL GERARD J | Director | Grant | 4K | $0.00 | $0 | 17K |
| 2026-01-06 | Mensinger Mike | Chief Product Officer | Sell | 2K | $30.10 | $66K | 81K |
| 2026-01-02 | Feider Stephen | Chief Financial Officer | Sell | 20K | $29.53 | $591K | 43K |
| 2026-01-02 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 20K | $5.10 | $102K | 63K |
| 2026-01-02 | Mensinger Mike | Chief Product Officer | Sell | 600 | $30.20 | $18K | 83K |
| 2026-01-02 | Mensinger Mike | Chief Product Officer | Sell | 7K | $29.56 | $213K | 84K |
| 2025-12-04 | Hopman Mark | Chief Commercial Officer | Sell | 2K | $30.66 | $63K | 136K |
| 2025-12-02 | Saint Sean | President & CEO | Sell | 3K | $29.34 | $96K | 98K |
| 2025-12-02 | Feider Stephen | Chief Financial Officer | Sell | 1K | $29.34 | $42K | 43K |
| 2025-12-02 | Mensinger Mike | Chief Product Officer | Sell | 1K | $29.34 | $31K | 91K |
| 2025-12-02 | Russell Steven Jon | Chief Medical Officer | Sell | 1K | $29.34 | $30K | 178K |
| 2025-12-02 | Hopman Mark | Chief Commercial Officer | Sell | 856 | $29.34 | $25K | 138K |
| 2025-12-01 | Lezack Adam | Director | Sell | 500 | $29.91 | $15K | 8K |
| 2025-12-01 | Lezack Adam | Director | Sell | 906 | $29.35 | $27K | 9K |
| 2025-12-01 | Palasis Maria | Director | Sell | 500 | $29.96 | $15K | 8K |
| 2025-12-01 | Palasis Maria | Director | Sell | 906 | $29.33 | $27K | 9K |
| 2025-10-31 | Lezack Adam | Director | Sell | 38 | $27.70 | $1K | 10K |
| 2025-10-31 | Lezack Adam | Director | Sell | 1K | $26.85 | $37K | 10K |
| 2025-10-31 | Palasis Maria | Director | Sell | 119 | $27.45 | $3K | 10K |
| 2025-10-31 | Palasis Maria | Director | Sell | 1K | $26.86 | $35K | 10K |
| 2025-10-03 | Feider Stephen | Chief Financial Officer | Sell | 1K | $22.28 | $26K | 44K |
| 2025-10-03 | Feider Stephen | Chief Financial Officer | Sell | 4K | $21.52 | $82K | 45K |
| 2025-10-03 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 5K | $5.10 | $25K | 49K |
| 2025-10-01 | Feider Stephen | Chief Financial Officer | Sell | 100 | $21.08 | $2K | 44K |
| 2025-10-01 | Feider Stephen | Chief Financial Officer | Sell | 15K | $20.76 | $310K | 44K |
| 2025-10-01 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 15K | $5.10 | $77K | 59K |
| 2025-09-08 | Feider Stephen | Chief Financial Officer | Sell | 10K | $21.13 | $209K | 44K |
| 2025-09-08 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 10K | $5.10 | $50K | 54K |
| 2025-09-05 | Hopman Mark | Chief Commercial Officer | Sell | 11K | $20.56 | $235K | 31K |
| 2025-09-05 | Hopman Mark | Chief Commercial Officer | Exercise or conversion | 11K | $5.10 | $58K | 43K |
| 2025-09-05 | Feider Stephen | Chief Financial Officer | Sell | 100 | $21.00 | $2K | 44K |
| 2025-09-05 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 100 | $5.10 | $510 | 44K |
| 2025-09-04 | Hopman Mark | Chief Commercial Officer | Sell | 7K | $19.97 | $136K | 31K |
| 2025-09-04 | Hopman Mark | Chief Commercial Officer | Exercise or conversion | 4K | $5.10 | $21K | 38K |
| 2025-09-04 | Hopman Mark | Chief Commercial Officer | Exercise or conversion | 656 | $5.10 | $3K | 34K |
| 2025-09-02 | Saint Sean | President & CEO | Sell | 3K | $18.86 | $63K | 101K |
| 2025-09-02 | Russell Steven Jon | Chief Medical Officer | Sell | 1K | $18.86 | $19K | 71K |
| 2025-09-02 | Mensinger Mike | Chief Product Officer | Sell | 1K | $18.86 | $21K | 92K |
| 2025-09-02 | Hopman Mark | Chief Commercial Officer | Sell | 848 | $18.86 | $16K | 33K |
| 2025-09-02 | Feider Stephen | Chief Financial Officer | Sell | 1K | $18.86 | $28K | 44K |
| 2025-08-22 | Feider Stephen | Chief Financial Officer | Sell | 4K | $17.01 | $75K | 46K |
| 2025-08-22 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 4K | $5.10 | $23K | 50K |
| 2025-08-19 | Hopman Mark | Chief Commercial Officer | Sell | 16K | $16.61 | $268K | 34K |
| 2025-08-19 | Hopman Mark | Chief Commercial Officer | Exercise or conversion | 16K | $5.10 | $82K | 50K |
| 2025-08-19 | Feider Stephen | Chief Financial Officer | Sell | 6K | $17.03 | $95K | 46K |
| 2025-08-19 | Feider Stephen | Chief Financial Officer | Exercise or conversion | 6K | $5.10 | $28K | 51K |
| 2025-06-02 | Saint Sean | President & CEO | Sell | 2K | $18.15 | $40K | 105K |
| 2025-06-02 | Saint Sean | President & CEO | Sell | 311 | $18.69 | $6K | 105K |
| 2025-06-02 | Saint Sean | President & CEO | Sell | 943 | $17.03 | $16K | 107K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON34 Form 144 notices on file for BBNX worth $5.3M at the prices reported; 10 in the last 90 days worth $2.4M. Latest: MARK HOPMAN filed on 2026-10-01 to sell 2,660 shares ($50K) from 2026-10-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-01 | MARK HOPMANOfficer | 3K | $50K | 0.006% | 2026-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-22 | CHRISTINA JONESDirector | 9K | $197K | 0.020% | 2026-09-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | MARK HOPMANOfficer | 28K | $541K | 0.063% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-16 | MICHAEL MENSINGEROfficer | 5K | $102K | 0.012% | 2026-09-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-09 | MARK HOPMANOfficer | 40K | $779K | 0.090% | 2026-09-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-03 | Steven Jon RussellOfficer | 4K | $82K | 0.009% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-03 | Sean SaintOfficer, Director | 17K | $327K | 0.037% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-03 | Stephen FeiderOfficer | 7K | $130K | 0.015% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-03 | Michael R. MensingerOfficer | 4K | $85K | 0.010% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-09-03 | Mark HopmanOfficer | 5K | $103K | 0.012% | 2026-09-02 | Morgan Stanley Smith Barney LLC |
| 2026-06-24 | CHRISTINA JONESDirector | 1K | $19K | 0.003% | 2026-06-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-04 | CHRISTINA JONESDirector | 3K | $35K | 0.006% | 2026-06-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-03 | Steven Jon RussellOfficer | 4K | $54K | 0.009% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-06-03 | Sean SaintOfficer, Director | 17K | $216K | 0.038% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-06-03 | Stephen FeiderOfficer | 7K | $85K | 0.015% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-06-03 | Michael R. MensingerOfficer | 4K | $56K | 0.010% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-06-03 | Mark HopmanOfficer | 5K | $68K | 0.012% | 2026-06-02 | Morgan Stanley Smith Barney LLC |
| 2026-05-21 | CHRISTINA JONESDirector | 2K | $20K | 0.004% | 2026-05-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-21 | ADAM LEZACKDirector | 2K | $20K | 0.004% | 2026-05-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-04 | Sean SaintOfficer, Director | 3K | $42K | 0.008% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-04 | Stephen FeiderOfficer | 1K | $18K | 0.003% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-04 | Michael R. MensingerOfficer | 1K | $13K | 0.002% | 2026-03-02 | Morgan Stanley Smith Barney LLC |
| 2026-03-04 | Mark HopmanOfficer | 353 | $4K | 0.001% | 2026-03-04 | Merrill Lynch |
| 2026-01-02 | Stephen FeiderOfficer | 20K | $591K | 0.045% | 2026-01-02 | Merrill Lynch |
| 2026-01-02 | MICHAEL MENSINGEROfficer | 10K | $305K | 0.023% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | Stephen FeiderOfficer | 20K | $591K | 0.045% | 2026-01-02 | Merrill Lynch |
| 2025-12-04 | Sean SaintOfficer, Director | 3K | $96K | 0.007% | 2025-12-02 | Morgan Stanley Smith Barney LLC |
| 2025-12-04 | Stephen FeiderOfficer | 1K | $42K | 0.003% | 2025-12-02 | Morgan Stanley Smith Barney LLC |
| 2025-12-04 | Michael R. MensingerOfficer | 1K | $31K | 0.002% | 2025-12-02 | Morgan Stanley Smith Barney LLC |
| 2025-12-04 | Mark HopmanOfficer | 2K | $63K | 0.005% | 2025-12-04 | Merrill Lynch |
| 2025-10-31 | ADAM LEZACKDirector | 3K | $75K | 0.006% | 2025-10-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-31 | MARIA PALASISDirector | 3K | $75K | 0.006% | 2025-10-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-03 | Stephen FeiderOfficer | 5K | $108K | 0.011% | 2025-10-03 | Merrill Lynch |
| 2025-10-01 | Stephen FeiderOfficer | 15K | $312K | 0.035% | 2025-10-01 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 70 shown. JSON22 holders report 5% or more of BBNX in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Associates, Inc. at 16.6% of the class (8,943,061 shares), filed 2026-10-07 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G | T. Rowe Price Associates, Inc.investment adviser | 8.9M | 16.6% | 2026-09-30 |
| 2026-08-13 | 13G/Ano. 5 | Dapice Joshua J.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Dreyfuss, Philip D.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Dunn Hannah E.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Gehani, Varun N.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Giauque, Nicolasparent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Husen, Avner A.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Kim, David T.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Linn, Michael G.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Luo Patrick (Cheng)parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Roberts, Jr., Thomas G.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Saito Edric C.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Wehrly, Mark C.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Warren, John R.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Short Daniel S.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Spokes, Andrew J. M.parent holding company, individual | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Management, L.L.C.investment adviser, other entity | 595K | 1.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Zone Healthcare Holdings, LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-07-24 | 13G | Divisadero Street Capital, LLCparent holding company, other entity | 3.1M | 6.9% | 2026-07-17 |
| 2026-07-24 | 13G | Divisadero Street Capital Management, LPinvestment adviser, partnership | 3.1M | 6.9% | 2026-07-17 |
| 2026-07-24 | 13G | William Zolezziparent holding company, individual | 3.1M | 6.9% | 2026-07-17 |
| 2026-07-24 | 13G | Divisadero Street Partners GP, LLCparent holding company, other entity | 2.6M | 5.9% | 2026-07-17 |
| 2026-07-24 | 13G | Divisadero Street Partners, L.P.partnership | 2.6M | 5.9% | 2026-07-17 |
| 2026-05-15 | 13G/Ano. 1 | Finny Kuruvilla, M.D., Ph. D.parent holding company, individual | 5.9M | 13.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Eventide Asset Management, LLCinvestment adviser | 5.9M | 13.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Robin C. Johnparent holding company, individual | 5.9M | 13.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | Roderick Wongparent holding company, individual | 2.0M | 4.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | RTW Investments, LPinvestment adviser, partnership | 2.0M | 4.5% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Levy Guyindividual | 4.4M | 9.8% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus GP, LLCother entity | 4.3M | 9.7% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Capital Management, L.P.partnership | 4.3M | 9.7% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Capital Master Fund, L.P.non-US institution | 2.6M | 5.9% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Capital Group, LLCother entity | 2.6M | 5.9% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Capital, LLCother entity | 2.6M | 5.9% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Private Equity GP II, LLCother entity | 1.7M | 3.8% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus Private Equity Fund II, L.P.partnership | 1.7M | 3.8% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 2 | Soleus PE GP II, LLCother entity | 1.7M | 3.8% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-23 | 13G | Steven A. Cohenindividual | 2.3M | 5.2% | 2026-02-18 |
13F holders
Tracked managers holding BBNX at their latest 13F. JSON4 of the 30 tracked managers held BBNX at their latest 13F, $55.3M in total at quarter-end prices. Point72 Asset Management is the largest at $35.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 2.3M | $35.3M | 0.04% | -270K |
| Millennium Management | 2026-06-30 | 956K | $15.0M | 0.01% | +95K |
| AQR Capital Management | 2026-06-30 | 308K | $4.8M | 0.00% | +248K |
| Renaissance Technologies | 2026-06-30 | 11K | $177K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Beta Bionics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Beta Bionics (BBNX), SEC CIK 1674632, listed on Nasdaq, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-29.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-14.JSON and CSV
- Company record
- EDGAR filing index for CIK 1674632Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of BBNX is sold short?
6,046,389 shares were held short at the 2026-09-30 settlement, 3.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BBNX's daily short volume?
On 2026-10-23, 237,459 of the 374,417 BBNX shares reported to FINRA were sold short, 63.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BBNX have fails to deliver?
The SEC's latest file shows 7,946 BBNX shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are BBNX insiders buying or selling?
Insiders at BBNX reported 13 open-market sells worth $2.4M in the last 90 days and no open-market buys. Latest filing: Hopman Mark (Chief Commercial Officer) on 2026-10-14.
Have BBNX insiders filed to sell?
34 Form 144 notices on file for BBNX worth $5.3M at the prices reported; 10 in the last 90 days worth $2.4M. Latest: MARK HOPMAN filed on 2026-10-01 to sell 2,660 shares ($50K) from 2026-10-01.
Who owns 5% or more of BBNX?
22 holders report 5% or more of BBNX in their latest filing, all on Schedule 13G (passive). The largest reported stake is T. Rowe Price Associates, Inc. at 16.6% of the class (8,943,061 shares), filed 2026-10-07 for an event on 2026-09-30.
Which tracked 13F managers own BBNX?
4 of the 30 tracked 13F managers held BBNX shares at their latest filing, $55.3M in all. The largest: Steve Cohen's Point72 Asset Management (2.3M shares, $35.3M), Izzy Englander's Millennium Management (956K shares, $15.0M), Cliff Asness's AQR Capital Management (308K shares, $4.8M), Renaissance Technologies (11K shares, $177K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.